Bluebird

bluebird bio to Present at Cowen Health Care Conference

Friday, February 26, 2021 - 1:00pm

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m.

Key Points: 
  • bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m.
  • To access the live webcast of bluebird bios presentation, please visit the Events & Presentations page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com .
  • A replay of the webcast will be available on the bluebird bio website for 90 days following the event.
  • bluebird bio is a trademark of bluebird bio, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005333/en/

bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress

Tuesday, February 23, 2021 - 9:05pm

bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.

Key Points: 
  • bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.
  • INTENT TO SEPARATE On January 11, 2021, bluebird bio announced its intent to separate its severe genetic disease and oncology businesses into two independent, publicly traded companies (bluebird bio and Oncology Newco).
  • The company also presented updated efficacy and safety results for pediatric patients in the Phase 3 HGB-207 (Northstar-2) and HGB-212 (Northstar-3) studies.
  • ZYNTEGLO, LentiGlobin, and bluebird bio are trademarks of bluebird bio, Inc.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

Tuesday, February 23, 2021 - 5:30pm

Investors suffering losses on their bluebird investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com .

Key Points: 
  • Investors suffering losses on their bluebird investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com .
  • On this news, bluebirds stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

bluebird bio to Present at Leerink Global Healthcare Conference

Monday, February 22, 2021 - 9:05pm

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference, Thursday, February 25, at 12:00 p.m.

Key Points: 
  • bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference, Thursday, February 25, at 12:00 p.m.
  • To access the live webcast of bluebird bios presentation, please visit the Events & Presentations page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com .
  • A replay of the webcast will be available on the bluebird bio website for 90 days following the event.
  • bluebird bio is a trademark of bluebird bio, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005851/en/

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors

Monday, February 22, 2021 - 4:00pm

Bluebird investors have until April 13, 2021 to file a lead plaintiff motion.

Key Points: 
  • Bluebird investors have until April 13, 2021 to file a lead plaintiff motion.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
  • On this news, bluebirds stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors

Thursday, February 18, 2021 - 12:11am

The Law Offices of Frank R. Cruz announces an investigation of Bluebird Bio, Inc. (bluebird or the Company) (NASDAQ: BLUE ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Bluebird Bio, Inc. (bluebird or the Company) (NASDAQ: BLUE ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • If you are a shareholder who suffered a loss, click here to participate.
  • On this news, bluebirds stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors

Wednesday, February 17, 2021 - 9:35pm

Law Offices of Howard G. Smith announces an investigation on behalf of bluebird bio, Inc. (bluebird or the Company) (NASDAQ: BLUE ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of bluebird bio, Inc. (bluebird or the Company) (NASDAQ: BLUE ) investors concerning the Companys possible violations of federal securities laws.
  • In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application (BLA) to the U.S. Food and Drug Administration (FDA) for LentiGlobin for sickle cell disease in the second half of 2021.
  • On this news, bluebirds stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Portnoy Law: Lawsuit Filed On Behalf of Bluebird Bio Inc. Investors

Tuesday, February 16, 2021 - 1:00pm

LOS ANGELES, Feb. 16, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Bluebird Bio, Inc. ("Bluebird" or "the Company") (NASDAQ: BLUE) investors that acquired securities between May 11, 2020 and November 4, 2020.

Key Points: 
  • LOS ANGELES, Feb. 16, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Bluebird Bio, Inc. ("Bluebird" or "the Company") (NASDAQ: BLUE) investors that acquired securities between May 11, 2020 and November 4, 2020.
  • Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.
  • It is alleged in this complaint that Bluebird made misleading and false statements to the market.
  • Bluebird presented insufficient data to support its U.S. Biologics Licensing Application submission for LentiGlobin for sickle cell disease.

Bluebird Network Acquires ColoHub Data Center in Quad Cities, Iowa

Tuesday, January 5, 2021 - 1:01pm

Bluebird Network a communications infrastructure provider and data center operator is excited to announce that effective December 31, 2020, it acquired the ColoHub Data Centerpreviously owned by Geneseo Communicationslocated in Bettendorf, Iowa.

Key Points: 
  • Bluebird Network a communications infrastructure provider and data center operator is excited to announce that effective December 31, 2020, it acquired the ColoHub Data Centerpreviously owned by Geneseo Communicationslocated in Bettendorf, Iowa.
  • Purchasing a second data center enhances Bluebirds data center service offerings, creating another option for customers moving applications closer to the edge and establishing a disaster recovery location to Bluebirds underground data center in Springfield, MO.
  • Supplementing Bluebirds unique Underground Data Center in Springfield, MO the acquisition of ColoHub enables the company to readily support their northeast customers with low-latency communications and redundant data center services.
  • For more information about Bluebird Network, its Underground Data Center and service capabilities visit: http://www.bluebirdnetwork.com .

bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

Tuesday, November 24, 2020 - 1:00pm

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m.

Key Points: 
  • bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m.
  • ET to review clinical data presented at the 62nd American Society of Hematology Annual Meeting and Exposition.
  • To access the live webcast of bluebird bios presentation, please visit the Events & Presentations page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com .
  • bluebird bio is a trademark of bluebird bio, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005587/en/